Circulating tumor DNA analysis:potential to revise adjuvant therapy for stage II colorectal cancer  

作　　者：Ning Zhu Hanguang Hu Ying Yuan 

机构地区：[1]Department of Medical Oncology,The Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China [2]Cancer Institute,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,The Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China [3]Cancer Center,Zhejiang University,Hangzhou,Zhejiang,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第10期3613-3615,共3页信号转导与靶向治疗（英文）

基　　金：supported by the Provincial Key R&D Program of Zhejiang Province(2021C03125 to Y.Y.);the National Natural Science Foundation of China(81872481 to Y.Y.)。

摘　　要：In the DYNAMIC multicenter phase 2 study recently published in The New England Journal of Medicine,Tie J.et al.demonstrated that a novel circulating tumor DNA(ctDNA)-guided regimen reduced the use of adjuvant chemotherapy without sacrificing recurrence-free survival in patients with stage II colorectal cancer(CRC).1 This was the first reported prospective,randomized,controlled trial of ctDNA-based interventional adjuvant treatment for stage II CRC.

关 键 词：ADJUVANT COLORECTAL al. 

分 类 号：R730.5[医药卫生—肿瘤]